

# March 2022 ICOC Meeting

## President's Report


**Maria T. Millan, MD**  
**President & CEO**



## OUR MISSION

Accelerating world class science  
to deliver transformative  
regenerative medicine treatments  
in an equitable manner to a  
diverse California and world






- Develop shared resources
- Build knowledge networks




- Advance therapies to marketing approval
- Create a manufacturing partnership network
- Expand Alpha Clinics Network
- Create Community Care Centers of Excellence



- Build a diverse and highly skilled workforce
- Deliver a roadmap for access and affordability

# 1Q' 2022 Update on Strategic Theme

## Advance World Class Science



**2004-March 2022= \$3.4B in Awards**



DISCOVERY

**\$1B\***



TRANSLATION

**\$452M**



CLINICAL

**\$1.1B\***



EDUCATION

**\$383M**



INFRASTRUCTURE

**\$485M**



**\$315.9M in Awards under Prop 14**



DISCOVERY

**\$22.1M**



TRANSLATION

**\$58.6M**



CLINICAL

**\$91.5M**



EDUCATION

**\$143.6M**




INFRASTRUCTURE


**\$3.4M**

\* First round of DISC2 and SCD collaboration (CLIN) were awarded with Prop 71 funds


Strategic Plan Development & Launch



\* First round of DISC2 and SCD collaboration (CLIN) were awarded with Prop 71 funds



# Investing in Diverse Therapeutic Modalities



*Based on # of awards funded in DISC, TRAN, and CLIN pillars since passage of Prop 14 (Jan 2021)*

# 1Q' 2022 Update on Strategic Theme

Deliver Real World Solutions



# Advancing Clinical Programs During Transition and Re-launch: New Clinical Trials and Expedited Regulatory Designations



**Phase 1 trial:** Cellular Therapy for *in utero* Myelomeningocele Repair



PI Diana Farmer, UC Davis



**Phase 2 trial:** Inducing Fetal Hemoglobin with gene therapy to treat Sickle Cell Disease



PI David Williams, Boston Children's  
*Via NHLBI-CIRM Cure Sickle Cell MOU*

*100% of clinical awards launched on time*  
Including

**Expedited Designations:**

- ✓ RMAT designation (ART-SCID at UCSF - PI: Morton Cowan)
- ✓ Fast-track designation (Immune-Onc Therapeutics – PI: Joseph Woodard)

# 1Q' 2022 Update on Strategic Theme

Create Opportunity for All




# Education Programs:

## Multiple "On-Ramps" to Create Opportunities for a Skilled and Diverse Workforce



New programs created, past programs restored, existing programs continued & All revised to advance DEI, mentorship and workforce development goals





- ✓ CIRM CNS Workshop to inform **shared resource and knowledge networks** concept development
- ✓ For Board Action today: **data sharing requirement** for CIRM awards
- ✓ For Board Action today: DISCO concept to fuel **basic and foundational research**



- ✓ **Alpha Clinics Expansion-** RFA open for applications based on approved Concept



- ✓ **Educational** awards launched and ICOC approved a new undergraduate EDUC program
- ✓ VP Med Affairs recruited to work with CIRM team, AAWG & ICOC to develop a Roadmap for Access and Affordability
- ✓ Review team incorporating **DEI** evaluation tools and refinements into review process

# Team Build to support CIRM's New Era under Prop 14

2021

April

May

June



**Claudette Mandac**  
Project Manager Review



**Mitra Hooshmand**  
Sr. SO Special Projects



**Vanessa Singh**  
HR Manager



**Pouneh Simpson**  
Director of Finance



**Alexandra Caraballo**  
GM Specialist



**Kevin Marks**  
General Counsel



**Michael Bunch**  
Business Services Officer



**Rosa Canet-Aviles**  
VP Scientific



**Uta Grieshammer**  
Sr. SO Scientific

2021

September

October

November



**Linda Nevin**  
Sr. SO, Review



**Stephanie Bautista**  
Sr. EA



**Marianne Villablanca**  
Assoc. Dir, Board Relations



**Katie Sharify**  
Communications Coordinator



**Esteban Cortez**  
Director of Marketing & Communications



**Lisa McGinley**  
Sr. SO, Therapeutics



**Mason Saia**  
Software Engineer

December


2022

January

March



**Maziar S Mohammadi**  
Sr. SO, Scientific



**CIRM's New**  
5-Year Strategic Plan



**Treecy Truc Nguyen**  
Project Manager, Therapeutics



**Sean Turbeville**  
Vice President, Medical Affairs & Policy